Caremark exits home infusion with $310 mil. sale of division to Coram.
CAREMARK EXITS HOME INFUSION WITH $310 MIL. SALE TO CORAM of the assets of Caremark's home infusion business under a definitive agreement announced Jan. 30. Caremark will receive "approximately $310 mil. in cash and securities, subject to post-closing adjustment, in exchange for the assets of its home infusion business," Caremark said. The figure breaks down to $210 mil. in cash, $75 mil. in 7% convertible subordinated notes and $25 mil in 12% non-convertible subordinated notes, Caremark said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth